Key result
A reduced plasma eicosapentaenoic acid-arachidonic acid (EPA-AA) ratio was independently associated with peripheral artery disease in Japanese patients (OR 11.7; 95% CI 3.0-45.8; P<.001).
Case-Control (n=70)
Odds Ratio: 11.7 (95% CI 3–45.8)
p-value: p=<.001
A reduced plasma eicosapentaenoic acid-arachidonic acid (EPA-AA) ratio is independently associated with the presence of peripheral artery disease in Japanese patients with atherosclerotic risk factors.
Association with PAD is hypothesis-generating; does not support clinical use of EPA-AA ratio pending prospective validation.
A reduced ratio of plasma eicosapentaenoic acid-arachidonic acid (EPA-AA) is a newly recognized atherosclerotic risk factor. This ratio has not been fully investigated in peripheral artery disease (PAD). Seventy Japanese patients with atherosclerotic risk factors were enrolled and divided into 2 groups, those with PAD (group A: n = 38) and those without PAD (group B: n = 32). The EPA-AA ratio (P = .001) and ankle-brachial index (ABI: P < .001) in group A were significantly lower than those in group B. Univariate and multivariate analyses demonstrated that EPA-AA, ABI, and prescription of clopidogrel had significant correlation with PAD. Given the appropriate cutoff values, EPA-AA (odds ratio [OR] = 11.7, 95% confidence interval [CI] = 3.0-45.8; P < .001) and ABI (OR = 44.0, 95% CI = 5.4-358.5; P < .001) are factors independently associated with PAD. In conclusion, this study demonstrated that reduced plasma EPA/AA may underlie PAD at least in Japanese.
No takes yet. Share an insight, caveat, or question.
Fujihara et al. (2012) conducted a case-control in Peripheral artery disease (n=70). Reduced plasma eicosapentaenoic acid-arachidonic acid (EPA-AA) ratio vs. Patients without peripheral artery disease was evaluated on Presence of peripheral artery disease (OR 11.7, 95% CI 3.0-45.8, p=<.001). A reduced plasma eicosapentaenoic acid-arachidonic acid (EPA-AA) ratio was independently associated with peripheral artery disease in Japanese patients (OR 11.7; 95% CI 3.0-45.8; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: